Latest Insider Transactions at Metagenomi, Inc. (MGX)
This section provides a real-time view of insider transactions for Metagenomi, Inc. (MGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Metagenomi, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Metagenomi, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Pamela Wapnick Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,559
-2.47%
|
$1,559
$1.86 P/Share
|
|
Sep 05
2024
|
Pamela Wapnick Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,265
-9.04%
|
$12,530
$2.88 P/Share
|
|
Apr 01
2024
|
Jian Irish |
BUY
Grant, award, or other acquisition
|
Direct |
70,471
+19.08%
|
-
|
|
Apr 01
2024
|
Luis Borges Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,316
+50.0%
|
-
|
|
Apr 01
2024
|
Matthew Wein |
BUY
Grant, award, or other acquisition
|
Direct |
10,397
+50.0%
|
-
|
|
Apr 01
2024
|
Pamela Wapnick Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,316
+50.0%
|
-
|
|
Apr 01
2024
|
Sarah B. Noonberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,763
+36.53%
|
-
|
|
Apr 01
2024
|
Simon Harnest |
BUY
Grant, award, or other acquisition
|
Direct |
11,552
+8.61%
|
-
|
|
Apr 01
2024
|
Simren Delaney |
BUY
Grant, award, or other acquisition
|
Direct |
6,931
+6.87%
|
-
|
|
Apr 01
2024
|
Brian C. Thomas Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,992
+4.55%
|
-
|
|
Feb 13
2024
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,000
+31.51%
|
$12,000,000
$15.0 P/Share
|
|
Feb 13
2024
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
839,175
+47.19%
|
-
|
|
Feb 13
2024
|
Bayer Healthcare LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,050,997
+26.01%
|
-
|
|
Feb 13
2024
|
Sebastian Bernales |
BUY
Conversion of derivative security
|
Indirect |
1,896,445
+50.0%
|
-
|
|
Feb 13
2024
|
Sebastian Bernales |
BUY
Conversion of derivative security
|
Direct |
513,004
+39.99%
|
-
|
|
Feb 09
2024
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$1,000,000
$10.25 P/Share
|